MIRM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MIRM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Mirum Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.71. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.02.
Mirum Pharmaceuticals's EPS (Basic) for the three months ended in Dec. 2023 was $-0.71. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.02.
Mirum Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2023 was $-0.71. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.02.
During the past 3 years, the average EPS without NRIGrowth Rate was 9.30% per year.
During the past 6 years, Mirum Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 9.30% per year. The lowest was 4.10% per year. And the median was 6.70% per year.
The historical data trend for Mirum Pharmaceuticals's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mirum Pharmaceuticals Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Earnings per Share (Diluted) | Get a 7-Day Free Trial | -4.58 | -4.09 | -2.77 | -4.02 | -4.00 |
Mirum Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Earnings per Share (Diluted) | Get a 7-Day Free Trial | -0.99 | -0.80 | -1.94 | -0.57 | -0.71 |
For the Biotechnology subindustry, Mirum Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Mirum Pharmaceuticals's PE Ratio distribution charts can be found below:
* The bar in red indicates where Mirum Pharmaceuticals's PE Ratio falls into.
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Mirum Pharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as
Diluted Earnings Per Share (A: Dec. 2023 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (-163.415 | - | 0) | / | 40.885 | |
= | -4.00 |
Mirum Pharmaceuticals's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as
Diluted Earnings Per Share (Q: Dec. 2023 ) | = | (Net Income | - | Preferred Dividends | / | Shares Outstanding (Diluted Average) |
= | (-35.659 | - | 0) | / | 46.621 | |
= | -0.76 |
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
Mirum Pharmaceuticals (NAS:MIRM) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Mirum Pharmaceuticals's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Peter Radovich | officer: Chief Operating Officer | C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
Jolanda Howe | officer: SVP, Global Controller | C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404 |
Lara Longpre | officer: Chief Development Officer | C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404 |
Pamela Vig | officer: Chief Scientific Officer | C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404 |
Christopher Peetz | director, officer: President and CEO | C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080 |
Patrick J Heron | director, 10 percent owner | 550 HAMILTON AVE., SUITE 100, PALO ALTO CA 94301 |
Michael G Grey | director, officer: Executive Chairman | C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121 |
Eric Bjerkholt | officer: Chief Financial Officer | 132 PURDURE AVENUE, KENGSINGTON CA 94708 |
Timothy P Walbert | director | 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062 |
Lon Cardon | director | C/O RENEO PHARMACEUTICALS, INC., 12230 EL CAMINO REAL, SUITE 230, SAN DIEGO CA 92130 |
Niall O'donnell | director | C/O RIVERVEST VENTURE PARTNERS, 101 SOUTH HANLEY RD., STE 1850, ST. LOUIS MO 63105 |
James E Flynn | 10 percent owner, other: Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Saira Ramasastry | director | 501 CANAL BLVD., RICHMOND CA 94804 |
Ian Clements | officer: SVP Finance & Communications | C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404 |
Edwin Jonathan Tucker | officer: Chief Medical Officer | C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404 |
From GuruFocus
By Business Wire • 09-05-2023
By Business Wire • 07-17-2023
By Business Wire • 01-11-2024
By Business Wire • 11-20-2023
By Business Wire • 09-26-2023
By Business Wire • 11-03-2023
By Business Wire • 08-11-2023
By Business Wire • 09-11-2023
By Business Wire • 11-13-2023
By Business Wire • 09-06-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.